Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

SONI MEDICARE LTD.

NSE : NABSE : 539378ISIN CODE : INE848R01018Industry : Hospital & Healthcare ServicesHouse : Private

BSE80.30-1.63 (-1.99 %)

PREV CLOSE ( ) 81.93

OPEN PRICE ( ) 80.30

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 3

TODAY'S LOW / HIGH ( )80.30 80.30

52 WK LOW / HIGH ( ) 22.2785.44

NSE

This Company is not listed in NSE

Select year

Particulars

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Mar 2020

Operational & Financial Ratios

Earnings Per Share (Rs)

-3.94

-1.58

-1.41

-1.34

-2.97

CEPS(Rs)

-2.72

-0.04

0.41

0.40

-1.19

DPS(Rs)

0.00

Book NAV/Share(Rs)

3.79

7.73

9.31

10.73

12.07

Tax Rate(%)

-3.34

-10.22

10.13

7.65

-74.51

Margin Ratios

Core EBITDA Margin(%)

-5.57

-0.77

0.72

4.06

0.67

EBIT Margin(%)

-2.84

0.36

0.24

1.11

-0.52

Pre Tax Margin(%)

-5.97

-2.22

-2.96

-3.91

-4.78

PAT Margin (%)

-6.17

-2.45

-2.66

-3.61

-8.34

Cash Profit Margin (%)

-4.25

-0.07

0.77

1.08

-3.33

Performance Ratios

ROA(%)

-8.46

-3.45

-3.35

-3.41

-8.12

ROE(%)

-68.46

-18.52

-14.05

-11.71

-21.89

ROCE(%)

-6.61

0.84

0.48

1.53

-0.68

Asset Turnover(x)

1.37

1.41

1.26

0.95

0.97

Sales/Fixed Asset(x)

1.32

1.36

1.15

0.83

0.82

Working Capital/Sales(x)

7.98

30.81

132.91

-6.20

-53.50

Efficiency Ratios

Fixed Capital/Sales(x)

0.75

0.74

0.87

1.20

1.22

Receivable days

99.82

93.31

82.72

81.06

58.63

Inventory Days

6.79

8.06

15.26

31.59

35.24

Payable days

228.88

217.88

189.32

370.70

296.72

Valuation Parameters

PER(x)

0.00

PCE(x)

-9.43

-463.46

72.00

79.72

0.00

Price/Book(x)

6.76

2.52

3.17

2.98

0.00

Yield(%)

0.00

EV/Net Sales(x)

0.71

0.59

0.86

1.26

0.63

EV/Core EBITDA(x)

-77.78

21.45

23.28

21.66

14.04

EV/EBIT(x)

-25.10

164.86

350.68

113.04

-122.17

EV/CE(x)

1.70

1.35

1.02

1.17

0.58

M Cap / Sales

0.40

0.30

0.56

0.86

0.00

Growth Ratio

Net Sales Growth(%)

-1.00

21.82

43.12

4.09

3.44

Core EBITDA Growth(%)

-133.11

-9.33

-9.34

34.54

-0.95

EBIT Growth(%)

-888.48

77.74

-68.59

324.26

-13.06

PAT Growth(%)

-149.82

-12.08

-5.45

54.98

-88.94

EPS Growth(%)

-149.82

-12.08

-5.45

54.98

-88.94

Financial Stability Ratios

Total Debt/Equity(x)

6.05

2.64

1.85

1.56

1.19

Current Ratio(x)

1.43

1.08

1.02

0.77

0.96

Quick Ratio(x)

1.36

1.04

0.94

0.66

0.76

Interest Cover(x)

-0.90

0.14

0.08

0.22

-0.12

Total Debt/Mcap(x)

0.89

1.05

0.58

0.52